Hoth Therapeutics inks deal to develop vaccine for Covid-19 [Seeking Alpha]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Seeking Alpha
Healthcare Hoth Therapeutics inks deal to develop vaccine for Covid-19 Mar. 23, 2020 8:36 AM ET | Hoth Therapeutics, Inc. (HOTH) Mamta Mayani Hoth Therapeutics (NASDAQ: joint venture entity VaxCelerate offers two unique elements to combat the Coronavirus - one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy. The vaccine focuses on both DNA and internal/external mutated proteins providing the immune system with more potential targets to attack. Pursuant to the agreement, Hoth shall be granted the right to receive single-digit royalties from the sale of any products developed, and shall have the right to acquire up to a 30% equity interest in HaloVax. Click to subscribe to real-time analytics on HOTH Now read: Aytu Bio to distribute Covid-19 IgG/IgM Rapid Test; shares up 15% premarket »
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease [TheStreet.com]TheStreet.com
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR Newswire
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide [TheStreet.com]TheStreet.com
- Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR Newswire
HOTH
Sec Filings
- 4/16/26 - Form 8-K
- 4/16/26 - Form 424B5
- 4/2/26 - Form 8-K
- HOTH's page on the SEC website